Somatostatin analogue SMS 201-995 long term therapy for vipoma.
The definitive treatment of a pancreatic tumour secreting vasoactive intestinal polypeptide is surgical removal of the tumour, but when curative resection is not possible symptomatic treatment of the endocrine hyperfunction is important. Streptozotocin, although effective for palliation, can involve unpleasant side effects. We report the long term use of subcutaneous somatostatin analogue SMS 201-995 in an elderly man presenting with severe watery diarrhoea and anaemia due to a pancreatic vipoma. Good symptomatic improvement has been achieved with no side effects over a period of 24 months. We suggest there is a use for subcutaneous SMS 201-995 in elderly patients with inoperable pancreatic gut hormone producing tumours with metastases and in those where surgery would carry a high operative risk.
D007516:Adenoma, Islet Cell / Q000188:drug therapy*; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001835:Body Weight; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D015282:Octreotide; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003969:Vipoma / Q000188:drug therapy*
D000970:Antineoplastic Agents; D013004:Somatostatin; D015282:Octreotide